Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
NEW YORK, Sept. 27, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
http://www.reportlinker.com/p01006955/Therapy-Trends--Multiple-Sclerosis----KOL-Insight--and-Consensus-Outlook-Modules.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Charting the Future Multiple Sclerosis Market Landscape
Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.
Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:
An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
A detailed forecast data analysis spreadsheet model comparing critical market parameters including
Timely event-driven market forecast report and data analysis updates over the next 12 months
Mapping Future Events to Product Sales Forecasts
The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2006–11) is based on company information, and the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.
Report features:
Historical MS sales from 2006–2011
Forecast MS sales from 2012-2016
Key competitors and drug developers
Predicted product positioning
Current and late-stage pipeline drugs
Future event mapping to forecast data points
Comparative clinical trial results
Interactive Product and Market Forecast Data Model
FirstWord's MS forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters.
Market size
Product sales
Company forecasts
Company, brand, and drug class
Mechanism of action
Future events
Forecasts and Analysis Updated Within Days of Major Market Events
Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event's occurrence.
Whether it's a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.
Understand the Unique Benefits of Consensus Outlook
Evaluate future sales forecasts and predicted market growth
Map your market parameters and chart commercial prospects
Assess market share by company and product
Tailor your strategic and investment focus based on the competition
Set proactive launch and branding strategies
Keep up with event-driven market data updates
Forecast Data Model (Excel)
Tabs:
Market size
Product sales
Company forecast
Mechanism of action
Events
Forecast Analysis Report (PDF)
Contents:
Analysis Highlights
Multiple Sclerosis Marketplace
Key Multiple Sclerosis Developers
Multiple Sclerosis Class Dynamics
Gilenya (fingolimod; Novartis Mitsubishi Tanabe) Forecast
Tysabri (natalizumab; Biogen/Elan) Forecast
Copaxone (glatiramer acetate; Teva) Forecast
Avonex (interferon beta-1a; Biogen) Forecast
Betaseron (interferon beta-1b; Bayer) Forecast
Rebif (interferon beta-1a; Merck) Forecast
Extavia (interferon beta-1b; Novartis) Forecast
BG-12 (dimethyl fumarate; Biogen) Forecast
Aubagio (teriflunomide; Sanofi) Forecast
Laquinimod (Teva/Active Biotech) Forecast
Lemtrada (alemtuzumab; Genzyme/Sanofi) Forecast
Daclizumab HYP (Biogen/Abbott) Forecast
Ocrelizumab (Biogen/Roche/Biogen) Forecast
To order this report:
Pathology Industry: Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article